Qilian International Holding Group Limited Market Cap ($105.36 Million)
Market Cap & Net Worth: Qilian International Holding Group Limited (BGM)
Qilian International Holding Group Limited market cap. Qilian International Holding Group Limited (NASDAQ:BGM) has a market capitalization of $105.36 Million ($105.36 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18835 globally and #4372 in its home market, demonstrating a 21.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qilian International Holding Group Limited's stock price $9.54 by its total outstanding shares 380623358 (380.62 Million). Also see Qilian International Holding Group Limit cash flow conversion for how efficiently the company converts equity into cash flow.
Qilian International Holding Group Limited Market Cap History (2021–2026)
Qilian International Holding Group Limited market cap history from 2021 to 2026. Data shows change from $4.89 Billion to $3.63 Billion (-24.42% CAGR). Check Qilian International Holding Group Limit (BGM) share price today for real-time trading data and today's change.
Index Memberships
Qilian International Holding Group Limited is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #522 of 976 |
Weight: Qilian International Holding Group Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Qilian International Holding Group Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qilian International Holding Group Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Qilian International Holding Group Limit annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
37.04x
Qilian International Holding Group Limited's market cap is 37.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $4.89 Billion | $57.10 Million | $3.15 Million | 85.71x | 1552.26x |
| 2022 | $1.36 Billion | $64.86 Million | $1.08 Million | 21.04x | 1267.59x |
| 2023 | $1.47 Billion | $46.47 Million | -$7.78 Million | 31.57x | N/A |
| 2024 | $3.22 Billion | $25.10 Million | -$1.44 Million | 128.15x | N/A |
| 2025 | $1.40 Billion | $37.92 Million | -$19.94 Million | 37.04x | N/A |
Competitor Companies of BGM by Market Capitalization
Companies near Qilian International Holding Group Limited in the global market cap rankings as of November 5, 2026. Also see BGM current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Qilian International Holding Group Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Qilian International Holding Group Limited (2021–2026)
Market capitalization of Qilian International Holding Group Limited from 2021 to today. Between 2021 and today, Qilian International Holding Group Limited's market cap moved from $4.89 Billion to $ 3.63 Billion, with a yearly change of -24.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.63 Billion | +158.54% |
| 2025 | $1.40 Billion | -56.33% |
| 2024 | $3.22 Billion | +119.20% |
| 2023 | $1.47 Billion | +7.51% |
| 2022 | $1.36 Billion | -72.11% |
| 2021 | $4.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Qilian International Holding Group Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $105.36 Million USD |
| MoneyControl | $105.36 Million USD |
| MarketWatch | $105.36 Million USD |
| marketcap.company | $105.36 Million USD |
| Reuters | $105.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Qilian International Holding Group Limited
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and… Read more